Synairgen shares soar after finding drug cuts Covid-19 severity
The inhaled product is a formulation of a naturally occurring protein that Synairgen has previously said may be deficient in those with greater susceptibility to Covid-19
20 July 2020 - 17:05
London — Shares of Synairgen, a tiny pharmaceutical firm born out of a UK university, soared as much as 552% after the company said its experimental drug cut the risk of developing the worst symptoms of Covid-19.
In a clinical trial involving 220 subjects, the probability of a patient requiring ventilation or dying dropped 79% for those who got Synairgen’s SNG001 versus those who received a placebo, the Southampton, England-based company said in a statement. Those receiving SNG001 also were more than twice as likely to fully recover from the illness, it added...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.